Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly LLY-0.39%decrease; red down pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion.

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro and ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...